Form 4: Myriad Genetics Director Daniel K. Spiegelman Sells Shares Under 10b5-1 Trading Plan

Director Daniel K. Spiegelman of Myriad Genetics sold a portion of his common stock holdings on June 3rd and 4th, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Daniel K. Spiegelman, a director at Myriad Genetics Inc., executed sales of common stock on June 3rd and June 4th, 2024.
• The sales were conducted under a Rule 10b5-1 trading plan.
• On June 3rd, 3,788 shares were sold at a price of $22.04 per share.
• On June 4th, another 3,788 shares were sold at a price of $22.05 per share.
• Following these transactions, Spiegelman directly owns 32,917 shares of Myriad Genetics common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the stock sales were conducted under a pre-arranged 10b5-1 trading plan, which doesn't necessarily reflect the director's current view of the company's performance.

Industry Context

Sales by company directors are a common occurrence and are often scrutinized by investors for insights into the company's prospects; however, sales under a 10b5-1 plan are pre-arranged and may not reflect the director's current sentiment.

Stakeholder Impact

• Shareholders may react to the news of a director selling shares, although the impact may be mitigated by the fact that the sales were pre-planned.

Key Dates